BPG is committed to discovery and dissemination of knowledge
Homepage
Online Submission
Number of total visits
30649166
Number of visits today
2210
Number of downloads
13089341
MEMBERSHIP
Cited by in F6Publishing
For:
Dermine S , Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med . 2019;8 .31703375 DOI: 10.3390/jcm8111907 ] [ Cited by in Crossref: 6] [ Cited by in F6Publishing: 4 ] [ Article Influence: 2.0 ] [ Reference Citation Analysis ]
Number
Citing Articles
1
Machairas N , Daskalakis K , Felekouras E , Alexandraki KI , Kaltsas G , Sotiropoulos GC . Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34 :130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574 ] [ Reference Citation Analysis ]
2
Ito T , Jensen RT . Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22 :685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651 ] [ Cited by in Crossref: 1] [ Article Influence: 0.5 ] [ Reference Citation Analysis ]
3
Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725 ] [ Reference Citation Analysis ]
4
D'Souza D , Golzarian J , Young S . Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions. Curr Treat Options Oncol 2020;21 :52. [PMID: 32447461 DOI: 10.1007/s11864-020-00751-x ] [ Cited by in Crossref: 3] [ Cited by in F6Publishing: 2 ] [ Article Influence: 1.5 ] [ Reference Citation Analysis ]
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA California Corporate Number: 3537345
